# A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

> **NCT05552157** · PHASE2,PHASE3 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 280 (estimated)

## Conditions studied

- Alzheimers Disease
- Dementia
- Alzheimers Disease, Familial

## Interventions

- **DRUG:** Remternetug (SC)
- **DRUG:** Matching Placebo (Remternetug)

## Key facts

- **NCT ID:** NCT05552157
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-22
- **Primary completion:** 2034-03-30
- **Final completion:** 2034-08-30
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05552157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05552157, "A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05552157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*